NCT01423110View on ClinicalTrials.gov

Efficacy, Safety and Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis

PHASE2CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

August 31, 2011

Primary Completion Date

May 31, 2012

Study Completion Date

May 31, 2012

Conditions
Sporadic Inclusion Body Myositis
Interventions
BIOLOGICAL

BYM338

BIOLOGICAL

Placebo

Trial Locations (3)

Unknown

Novartis Investigative Site, Scottsdale

Novartis Investigative Site, Kansas City

Novartis Investigative Site, Boston

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY